in my view Neuren is no longer a speculative stock but has moved into the blue chip territory. Provided it is not taken over by BP it will end up ranking up there with CSL. The chance of success in the other 3 trials has very much improved imho. The chance of success in ph3 trials of NNZ2591 in PMS has also very much improved, based on where we were at with NNZ2596 at the end of Ph2 trials for Retts syndrome. 2591 has given better results with less adverse effects than 2596 did 2 or 3 years ago.
Ann: P2 trial shows significant improvements in Phelan-McDermid, page-94
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.71 |
Change
0.000(0.00%) |
Mkt cap ! $2.644B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 350 | $30.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.68 | 45 | 1 |
View Market Depth
| Last trade - 16.16pm 24/05/2024 (20 minute delay) ? |
| NEU (ASX) Chart |
Day chart unavailable